Sabrina Chiloiro

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

In this case report, we described the pitfalls in the differential diagnosis of a pituitary stalk lesion in a patient affected by Klinefelter Syndrome (KS) that was initially suspected of infundibulo-neuro-hypophysitis (INH). According to the atypical radiological picture for INH, the not-conclusive pathology findings, and the partial response to glucocorticoid treatment, a [18F] fluorocholine ([18F] FCH) positron emission computed tomography (PET-CT) scan was performed and identified a pituitary stalk proliferative lesion that was suggestive for neoplasia. This clinical case emphasizes the prospective and potential diagnostic role of the [18F] FCH PET-CT in pituitary stalk lesions and in the diagnosis of pituitary germinoma. Our article also includes a brief review of the literature, focusing on the differential diagnosis of lesions involving the pituitary stalk, the oncological risk associated with KS, and the role of nuclear imaging in the evaluation of such cases.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

While most individuals with familial medullary thyroid carcinoma (fMTC) carry RET mutations, in some instances the causative mutations remain unknown. We studied two related families with RET-negative fMTC in 21 affected individuals through linkage analysis, exome/genome sequencing, and high-density array comparative genomic hybridization. We identified a novel heterozygous 40kb intragenic SLC30A9 deletion which segregated with the disease in all affected individuals. The mutant transcript escaped nonsense-mediated decay and resulted in the production of N-terminally truncated proteins via translation reinitiation from in-frame AUG codons located downstream of the deletion. These proteins showed increased stability and their expression in an MTC cell line increased cell proliferation and clonogenic capacity, supporting an oncogenic role. These findings expand the genetic background of fMTC beyond RET mutations and implicate translation reinitiation in the etiology of cancer susceptibility syndromes secondary to structural genomic variants.

Year:

2026

Background Pasireotide long-acting release (PasiLAR), a somatostatin multireceptor ligand, is effective in achieving biochemical control but can increase the risk of hyperglycemia in acromegaly. However, the impact of PasiLAR on lipid and glucose metabolism in patients with acromegaly has not been systematically studied. This systematic review aimed at synthesizing evidence on PasiLAR effects (as monotherapy or combination therapy with pegvisomant) on lipid and glucose metabolism in patients with acromegaly. Methods MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2000 and 2024. Prospective and retrospective studies reporting metabolic outcomes before and under PasiLAR treatment for a minimum follow-up of 6 months. Two reviewers screened eligible publications (3441), extracted outcomes, and assessed risk of bias. Results Nineteen studies (896 patients) were included in the meta-analysis. PasiLAR was associated with increased fasting plasma glucose (FPG) (mean difference [MD] 23.4 mg/dL, 95% confidence interval [95%CI] 18.8–28.1]) and glycated hemoglobin (HbA 1c ) (MD 0.5%, 95%CI 0.4–0.7). A higher frequency of diabetes mellitus (DM) was observed after treatment (odds ratio 3.7, 95%CI 2.9–4.7). No significant changes in triglycerides, total cholesterol, or low-density lipoprotein cholesterol (LDL-C), and a modest but significant increase in high-density lipoprotein cholesterol (HDL-C) were recorded (MD 6.2 mg/dL, 95%CI 1.4–10.9]). Conclusions In this large meta-analysis, PasiLAR was associated with increased HDL-C, FPG, HbA1c, and frequency of DM in patients with acromegaly. There was no effect on triglycerides, total cholesterol, and LDL-C. PROSPERO registration number CRD42024544686.

Year:

2025

Purpose A paradoxical increase in GH after oral glucose load (GH-Par) characterizes about one-third of acromegaly patients and is associated with a better response to first-generation somatostatin receptor ligands (fg-SRLs). Pasireotide is typically considered as a second-/third-line treatment. Here, we investigated the predictive role of GH-Par in pasireotide response and adverse event development. Methods we collected a multicenter Italian retrospective cohort of 59 patients treated with pasireotide for at least 3 months, all having GH profile from OGTT. IGF-1 normalization or at least 30% reduction at the last follow-up visit defined a responder patient. Results Considering the entire cohort, median IGF-1 levels before pasireotide (available in 57 patients) were 1.38 times the upper limit of normal (ULN) in patients with large (median size 18 mm) and invasive (82%) adenomas after failure of fg-SRL treatment. After a 40-month median treatment, pasireotide effectively reduced IGF-1 ULN levels in 41 patients, 37 of whom achieving normalization, and 4 with a ≥ 30% reduction. Thirteen patients were classified as GH-Par. The median pasireotide duration, dosage, and efficacy (9/12 responder in the GH-Par group and 32/45 in the GH-NPar) were similar between groups. However, the occurrence of new-onset or worsening glucose metabolism alterations (GMAs) after pasireotide was more frequent in GH-NPar (from 37 to 80%; p < 0.001) compared to GH-Par patients (from 69 to 76%), likely due to the higher prevalence of pre-existing GMAs in the GH-Par group before starting pasireotide (p = 0.038). Conclusions The GH-Par does not predict the response to pasireotide in acromegaly but can predict a worse metabolic profile.

Year:

2025

Pituitary tumor-transforming gene 1 (PTTG1), discovered in 1997 by Pei and Melmed, takes part in cellular replication, cell cycle control, DNA repair mechanisms, organogenesis, metabolism regulation, cellular transformation, and senescence. Its biological actions include protein–protein interactions, modulation of gene transcription, and other than intracellular and autocrine mechanisms, even paracrine activities. For the reasons mentioned above, PTTG1 stands out as a multifaceted regulator of cancer biology; it is involved in genomic and chromosomal instability, local invasiveness, neo-lymphangiogenesis, and metastatic spreading. In solid neoplasms, endocrine neoplasms, although deemed rare, have experienced a significant increase in diagnostic incidence in recent years. Endocrine cancers are still a major challenge in healthcare and research since several questions remain unanswered, even though researchers have made considerable efforts to uncover their causes. Twenty-seven years have passed since PTTG1’s discovery, and several works have been published. However, only the tip of the iceberg has been unveiled. Herein, we review current knowledge of PTTG1’s action in endocrine cancers, such as pituitary, thyroid, testicular, adrenal, pancreatic, and ovarian.

Year:

2025

Purpose The tumor microenvironment (TME) may provide a useful framework for understanding the heterogeneous behavior of growth hormone (GH) secreting pituitary adenomas. Although the interest in TME in somatotropinomas has increased exponentially over the last few decades, there is limited elucidation of its mechanisms, particularly in relation to genes expression involved in its regulation. Methods A retrospective, observational, single-center study was conducted on 85 subjects: 46 patients diagnosed with acromegaly and 39 controls. After DNA extraction, clinical exome sequencing was performed and genomic alterations were detected, classified, and filtered using a dedicated bioinformatics pipeline. Results 5759 unique genetic variants were found in patients with acromegaly. 33 patients (72%) showed the presence of at least one pathogenic variant in at least one of the following genes: FANCD2, SPTA1, TYRO3, and ZNF335. The enrichment pathway analysis of mutated genes was performed and showed that these genes were included in the same genetic pathway called “regulation of lymphocyte activation” (GO:0051249). Inflammatory infiltrate was analyzed in histological samples in 26 patients. A significantly higher number of CD68 + macrophages (P-value = 0.008), a lower number of CD8 + T lymphocytes (P-value = 0.037) and a higher CD68 + macrophages/ CD8 + T-lymphocytes ratio (P-value = 0.004) were observed in patients with pathogenic variants of genes of “regulation of lymphocyte activation” pathway. Conclusion This study provides new insights into the genetic basis of the TME in somatotropinomas and suggests that genetics may influence immune cells infiltration in acromegaly.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (29)

Federica Begalli

Lecturer in Endocrinology

Queen Mary University of London

UNITED KINGDOM
View details

Emanuela TEVERONI

Staff Scientist

Università Cattolica del Sacro Cuore

ITALY
View details

Daniela Esposito

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

William Foulkes

Full Professor

McGill University

CANADA
View details

Giovanna Mantovani

University of Milan

ITALY
View details

FRANCESCA DASSIE

University of Padua

ITALY
View details

Marton Doleschall

senior scientist

Semmelweis University

HUNGARY
View details

Francesco Doglietto

Associate Professor

Università Cattolica del Sacro Cuore

ITALY
View details

Diego Ferone

Assistant Professor

University of Genova

ITALY
View details

Horia Constantin Stanescu

University College London

UNITED KINGDOM
View details

Simona Gaudino

Agostino Gemelli University Polyclinic

ITALY
View details

Michael Witcher

Associate Professor

Lady Davis Institute for Medical Research

CANADA
View details

Maralyn Druce

-

UNITED KINGDOM
View details

Jolanta Krajewska

Associate Professor

Maria Sklodowska-Curie Institute - Oncology Center Gliwice Branch

POLAND
View details

Anne Barlier

Aix-Marseille University

FRANCE
View details

Tommaso Tartaglione

Reasercher - Aggregate Professor

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia

ITALY
View details

Maria Alevizaki

Professor of Endocrinology

National and Kapodistrian University of Athens

GREECE
View details

Gianluca Occhi

Associate Professor

University of Padua

ITALY
View details

Márta Korbonits

Deputy Director of the William Harvey Research Institute

Queen Mary University of London

UNITED KINGDOM
View details

Andrea Giustina

Università Vita Salute San Raffaele

ITALY
View details

Federico Gatto

University of Genova

ITALY
View details

Donato Iacovazzo

NIHR Clinical Lecturer

Queen Mary University of London

UNITED KINGDOM
View details

Malgorzata Oczko-Wojciechowska

Head of Department/Ph.D

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details

Jes Mathiesen

University of Southern Denmark

DENMARK
View details

Maria Fleseriu

Oregon Health & Science University

UNITED STATES
View details

R Mihai

Oxford University Hospitals NHS Foundation Trust

UNITED KINGDOM
View details

Suvi Savola

Head of Oncogenetics

MRC-Holland

NETHERLANDS
View details

James R. Lupski

-

UNITED STATES
View details

Miklós Tóth

professor

Semmelweis University

HUNGARY
View details